Experimental Pharmacology and Drug Development for Parkinson's Disease: Translating Animal Models to Clinical Outcomes

This review examines how animal models have been used to evaluate novel compounds for Parkinson's disease treatments, including drugs targeting levodopa-induced dyskinesia, disease modification, and parkinsonism symptoms. The authors analyze multiple clinical trial candidates and discuss both successes and failures in predicting clinical efficacy from preclinical studies, offering insights into optimizing animal model design for better translational success.